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ABSTRACT
Objectives To use electronic health records (EHR) to
predict lifetime costs and health outcomes of patients
with stable coronary artery disease (stable-CAD) stratiﬁed
by their risk of future cardiovascular events, and to
evaluate the cost-effectiveness of treatments targeted at
these populations.
Methods The analysis was based on 94 966 patients
with stable-CAD in England between 2001 and 2010,
identiﬁed in four prospectively collected, linked EHR
sources. Markov modelling was used to estimate lifetime
costs and quality-adjusted life years (QALYs) stratiﬁed by
baseline cardiovascular risk.
Results For the lowest risk tenth of patients with
stable-CAD, predicted discounted remaining lifetime
healthcare costs and QALYs were £62 210 (95% CI
£33 724 to £90 043) and 12.0 (95% CI 11.5 to 12.5)
years, respectively. For the highest risk tenth of the
population, the equivalent costs and QALYs were
£35 549 (95% CI £31 679 to £39 615) and 2.9 (95%
CI 2.6 to 3.1) years, respectively. A new treatment with
a hazard reduction of 20% for myocardial infarction,
stroke and cardiovascular disease death and no side-
effects would be cost-effective if priced below £72 per
year for the lowest risk patients and £646 per year for
the highest risk patients.
Conclusions Existing EHRs may be used to estimate
lifetime healthcare costs and outcomes of patients with
stable-CAD. The stable-CAD model developed in this
study lends itself to informing decisions about
commissioning, pricing and reimbursement. At current
prices, to be cost-effective some established as well as
future stable-CAD treatments may require stratiﬁcation by
patient risk.
INTRODUCTION
Cardiovascular disease (CVD) is a leading cause of
mortality in England with approximately a third of
all deaths attributed to it.1 The combination of an
ageing population and improvements in survival
after acute coronary syndrome2 has resulted in a
large and growing number of patients with stable
coronary artery disease (stable-CAD). CVD has,
therefore, also become a major source of morbidity
and healthcare resource use: there are >5 million
people living with CVD in England costing the
National Health Service (NHS) more than £30
billion per year.3 4 The stable-CAD population
serves as an important example of a patient popula-
tion suffering from a long-term condition.
With such conditions becoming increasingly preva-
lent, questions regarding their prognosis have
become increasingly important.5 6 The prognosis
for patients with stable-CAD is particularly topical
with new treatments,7 and new applications of
existing treatments,8 currently undergoing phase III
trials in this patient population.
Thus far, the majority of models to estimate the
costs and health effects of CVD have focused on
primary prevention,9 10 have made predictions only
over relatively short time horizons (up to 10
years)11 so are unable to estimate lifetime costs and
health effects, are based on selected samples12
potentially biasing baseline risk and cost estimates
hence limiting their generalisability or fail to model
all relevant endpoints and their interdependence.13
The use of linked electronic health records (EHR)
can help to address many of these limitations in
modelling the costs and outcomes in chronic dis-
eases providing a source of long-term data, captur-
ing a wide range of clinical endpoints and
recording resource use in a real-world setting. As
far as we are aware, there has been limited use of
EHR in decision modelling.
The availability of primary care data linked with
hospitalisation data, disease-speciﬁc registries and
mortality data makes the English NHS an attractive
setting in which to develop and demonstrate our
approach for modelling the long-term costs and out-
comes of chronic disease. The CALIBER
(CArdiovascular disease research using Linked
BEspoke studies and Electronic Health Records)
data platform14 used in this study combines these
key datasets and has been shown to be a valuable
resource for cardiovascular epidemiology.12 15–17
This paper reports on the use of CALIBER to model
prognosis in patients with stable-CAD, estimating
their baseline risk of experiencing further CVD
events and then predicting both costs and key health
outcomes over the lifetime of these patients strati-
ﬁed by their baseline CVD risk. In doing so, the
model provides a better understanding of the impli-
cations of this growing population under current
standards of care as well as a framework for the
evaluation of the cost-effectiveness of new treatment
strategies, potentially differentiated by risk group.
METHODS
Patient population
The model was based on the analysis of 94 966
patients with stable-CAD from the CALIBER
Open Access
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collaboration. CALIBER links primary care data from the
Clinical Practice Research Datalink with EHR from the
Myocardial Ischaemia National Audit Project Registry, hospital
inpatient records from Hospital Episode Statistics and cause-
speciﬁc mortality from the Ofﬁce for National Statistics. The
CALIBER dataset has been described in detail by Denaxas
et al.
14 Patients with stable-CAD were deﬁned as those patients
in the CALIBER dataset who were event free for at least
6 months after having had unstable angina, STelevation myocar-
dial infarction (STEMI) or non-STEMI (NSTEMI) or those
patients with stable angina or other coronary heart disease
(CHD) diagnoses. The median follow-up of these patients was
4.2 (IQR 1.9–6.9) years, during which 16 783 patients died and
8203 patients experienced one or more non-fatal coronary
outcomes.
Endpoints
The primary clinical endpoints were ﬁrst occurrences of non-
fatal myocardial infarction (MI), ischaemic stroke and haemor-
rhagic stroke, as well as CVD and non-CVD mortality. Other
clinical endpoints were CVD and non-CVD mortality following
a non-fatal event. These were combined to produce the primary
economic outputs from the model which were quality-adjusted
life years (QALYs) as well as total and CVD-speciﬁc costs, each
predicted over the remaining lifetime of the patient. The model
was also used to produce estimates of event rates and disease
progression over time stratiﬁed by baseline CVD risk.
Model
A state transition model (shown in ﬁgure 1) was developed to
capture the natural history of patients with stable-CAD. The
structure of the model was determined with reference to both
previous models in CVD13 and expert clinical advice. All
patients entered the model in the stable-CAD state and pro-
gressed through the model until they experienced either CVD
or non-CVD mortality. The time horizon of the model was,
therefore, the patient’s remaining lifetime. The model captured
time varying and age-dependent risks, costs and health-related
quality of life (HRQoL) in 90-day segments. Costs and HRQoL
were attached to model states and, in order to stratify by
patients’ baseline risk, adjusted for patient covariates at baseline
as well as for age and for time elapsed following non-fatal
events. Model predicted costs, life years and QALYs were dis-
counted at 3.5% per annum in keeping with the guidelines in
England.18 While only ﬁrst occurrences of non-fatal CVD
events were explicitly modelled, further non-fatal events were
implicitly captured in the time varying risk, cost and HRQoL
estimates.
Statistical modelling of risk equations
Rapsomaniki et al19 developed, tested and validated a range of
prognostic models for patients with stable-CAD using the
CALIBER dataset. We built on their recommended prognostic
model, using it as the basis for the risk equations underpinning
the prediction of the ﬁve primary clinical endpoints. Using the
prognostic factors and missing data imputation algorithm of
Rapsomaniki et al19 we estimated various parametric survival
models (generalised gamma, lognormal, Weibull, exponential)
for each of the ﬁve endpoints. For each endpoint the best
ﬁtting parametric model was selected as determined by the
Akaike information criteria. Predictions resulting from the
selected models were assessed for plausibility by clinical
experts (AT, CPG, ADS, HH). Key prognostic factors included
in the models were demographic measures (age, sex, social
deprivation), stable-CAD subtype (stable angina, unstable
angina, STEMI, NSTEMI and other CHD), use of long-acting
nitrates, whether coronary artery bypass graft or percutaneous
coronary intervention (PCI) had been performed in the
6 months following CAD diagnosis, previous MI, smoking,
blood pressure, diagnosis of hypertension, diabetes, lipids,
Figure 1 Structure of the Markov model and the role played by the 11 risk equations that we use to model disease progression.
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CVD comorbidities (heart failure, peripheral arterial disease,
atrial ﬁbrillation, stroke), non-CVD comorbidities (chronic
renal disease, chronic obstructive pulmonary disease, cancer,
chronic liver disease), psychosocial factors (depression, anxiety)
and clinically assessed biomarkers (heart rate, white cell count,
haemoglobin, creatinine).
Risk equations for the six subsequent events, namely, CVD
and non-CVD mortality following non-fatal MI, ischaemic
stroke and haemorrhagic stroke, were estimated in a similar way.
However, due to the greatly reduced numbers of events
observed, these use only sex and age at time of non-fatal event
as covariates. Non-CVD mortality beyond the maximum
Table 1 Patient characteristics by risk group
Risk group Lowest risk 2 3 4 5 6 7 8 9 Highest risk Overall
Patient average covariate profiles based on tenths of patient population grouped by 5-year risk of composite CVD event estimated at baseline
Number of patients in dataset 10 035 9903 9797 9626 9516 9455 9382 9335 9249 8668 94 966
5-year risk (%; average across patients) 3.69 5.70 7.37 9.15 11.20 13.71 17.14 22.14 30.42 52.37 16.68
5-year risk (%; at average covariate values) 3.46 5.43 6.95 8.53 10.36 12.57 15.64 20.07 27.23 44.18 11.64
Sociodemographic characteristics
Sex (% female) 64 48 42 39 37 37 38 42 44 46 44
Age (years if male) 49 55 59 62 65 67 71 74 77 81 67
Age (years if female) 53 62 67 70 73 75 78 80 83 87 72
Age (weighted average) 52 59 62 65 68 70 73 76 80 84 69
Most deprived quintile (%) 15 17 18 19 20 21 21 22 22 24 20
Stable-CAD diagnosis (%)
NSTEMI 0 1 3 5 8 10 12 17 23 43 10
STEMI 1 4 8 12 13 14 13 9 6 4 7
Unstable angina 10 13 12 12 12 12 13 15 17 15 14
Stable angina 78 65 56 49 43 39 37 34 29 18 47
Non-specific CHD 11 17 20 22 24 24 25 26 25 20 23
Stable-CAD severity (%)
PCI in past 6 months 9 12 13 14 13 13 11 9 6 4 9
CABG in past 6 months 9 7 6 5 5 4 4 3 2 1 4
Previous/recurrent MI 2 6 10 14 18 23 26 29 32 43 18
Use of nitrates 10 16 19 21 24 28 33 37 43 56 28
CVD risk factors
Smoking status (%)
Current smoker 31 35 36 37 38 38 37 35 32 30 35
Ex-smoker 27 30 31 32 32 33 34 34 34 34 32
Never smoked 41 35 33 31 30 29 29 31 33 36 33
Hypertension (%) 69 70 71 71 72 74 76 79 83 87 76
Diabetes (%) 4 8 10 12 14 16 18 21 24 32 16
Total cholesterol (mmol/L) 4.95 4.91 4.84 4.79 4.74 4.74 4.70 4.68 4.64 4.54 4.79
HDL (mmol/L) 1.41 1.37 1.35 1.35 1.35 1.35 1.36 1.37 1.37 1.35 1.37
CVD comorbidities (%)
Heart failure 5 7 9 12 15 19 27 37 52 73 26
Peripheral arterial disease 1 2 3 4 6 8 10 13 16 25 8
Atrial fibrillation 3 5 7 9 10 13 16 21 29 43 15
Stroke 0 1 1 2 3 5 8 14 22 39 9
Non-CVD comorbidities (%)
Chronic kidney disease 2 2 3 4 4 5 7 9 12 20 7
Chronic obstructive pulmonary disease 20 20 20 21 22 23 25 27 28 30 23
Cancer 4 5 6 7 8 9 11 13 14 12 9
Chronic liver disease 0 1 1 1 1 1 1 1 1 1 1
Psychosocial characteristics
Depression at diagnosis (%) 20 17 15 15 14 14 15 17 18 21 17
Anxiety at diagnosis (%) 7 6 6 7 7 7 8 8 10 12 8
Biomarkers
Heart rate (bpm) 72 71 71 71 71 71 72 73 74 76 72
Creatinine (mmol/L) 88 92 95 96 98 100 101 104 109 125 100
White cell count (109/L) 6.81 7.05 7.19 7.31 7.44 7.54 7.62 7.76 7.88 8.22 7.46
Haemoglobin (g/100 mL) 1.43 1.43 1.42 1.41 1.39 1.37 1.35 1.32 1.28 1.22 1.36
Deprivation measured by index of multiple deprivation, 2010. All values in table are means. Percentage of missing data imputed: smoking status 32%, total cholesterol 54%, HDL 55%,
heart rate 78%, creatinine 38%, white cell count 56% and haemoglobin 53%.
CABG, coronary artery bypass graft; CAD, coronary artery disease; CHD, coronary heart disease; CVD, cardiovascular disease; HDL, high-density lipoprotein; MI, myocardial infarction;
NSTEMI, non-ST segment elevation myocardial infarction; PCI, percutaneous coronary intervention; stable-CAD, stable coronary artery disease; STEMI, ST segment elevation myocardial
infarction.
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follow-up in the CALIBER dataset (10 years) was based on
age/sex-speciﬁc non-CVD mortality from national life tables.20
These risk equations were developed into cumulative inci-
dence functions which were then combined using a competing
risks framework to account for the interdependence of the out-
comes. We used methods outlined by Putter et al21 that acknow-
ledge state transition probabilities are affected by the event
being modelled and also by the other events that could occur
from a given health state. Survival models were estimated using
R (V.3.1.0) and the R package ﬂexsurv (V.0.3).
Resource use and costs
Healthcare resource use was estimated directly from the
CALIBER dataset. A panel was constructed using a 90-day cycle
length for patients with stable-CAD in CALIBER capturing
resource use in terms of hospital episodes, use of drugs, diag-
nostic tests and primary care consultations. Costs were attached
to this resource use using the NHS reference costs,22 NHS pre-
scription cost analysis23 and Personal Social Services Research
Unit (PSSRU) unit costs for primary care24 datasets. All costs
were calculated from a health systems perspective and based on
the price year 2011/2012. Panel data models were used to esti-
mate patient costs adjusted for the prognostic factors used in the
model, as well as for the key CVD events in the model. This
allowed us to attach costs to model states adjusted for baseline
patient characteristics and event history.
Health-related quality of life
HRQoL estimates were not available from the CALIBER
dataset. Instead a catalogue of EQ-5D scores for the UK25 was
used to calculate age-speciﬁc, condition-speciﬁc and event-
speciﬁc HRQoL. These were attached to states in the model to
calculate patient-speciﬁc estimates of remaining lifetime QALYs.
Analysis
Given that the model was designed to be used with a heteroge-
neous population, results were produced stratiﬁed by risk group.
The 5 year baseline risk of experiencing at least one CVD event
for each patients with stable-CAD in the CALIBER dataset was
predicted based on the estimated risk equations given the
patient’s baseline covariate values as input parameters. The base-
line values were those from the prognostic factors used in the
risk equations measured at the point that the patient entered
into the stable-CAD cohort. Patients were ranked by risk predic-
tions and grouped into 10 equally sized risk groups. Model
results were calculated at the mean baseline covariate value
across patients within each risk group. In addition, estimates
were predicted for a representative patient within each of the 10
risk groups demonstrating both the population-level and patient-
level results produced by the model. The model was evaluated
probabilistically by means of a Monte Carlo simulation run for
1000 iterations in order to incorporate and characterise the
uncertainty in the model inputs.26
Figure 2 Proportion of patients in each of the six model states over time as predicted by the Markov model used in this study. Each plot within
the panel represents a risk decile as categorised by the baseline 5-year CVD event risk ranging from the lowest risk decile (1) to the highest risk
decile (10). As can be seen in the plots the model is run until all the patients in the cohort have experienced either a fatal CVD or a fatal non-CVD
event. CVD, cardiovascular disease; MI, myocardial infarction.
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The model was used to calculate life expectancy, QALYs, total
healthcare costs and CVD-speciﬁc healthcare costs for standard
care, as well as for indicative new treatments assumed to reduce
CVD risks by 10%, 20%, 30% and 40%. The indicative treatments
were assumed to have constant costs and treatment effects, no
direct effect on the risk of non-CVD mortality and no side-effects.
When interpreting the results of this analysis it should be recog-
nised that these assumptions may not hold in practice. The results
were used to estimate the maximum price that could be charged
for the new treatments in each of the risk groups assuming a range
of cost-effectiveness thresholds between £10 000 and £40 000 per
QALY. National Institute for Health and Care Excellence (NICE)
employ a threshold ranging between £20 000 and £30 000 per
QALY18 for considering an intervention cost-effective in England,
and recent empirical evidence provides a central estimate of the
threshold in England of approximately £13 000 per QALY.27
Further details about the (a) patients with stable-CAD in the
CALIBER dataset, (b) the economic model, (c) the estimation of
costs and transition probabilities for use in the model, (d) the
risk equations used to estimate model transition probabilities,
(e) patient proﬁles for the 10 representative patients and (f )
extended tables of results can be found in the accompanying
online supplementary material appendices. The full model
source code detailing all calculations performed in the model,
including the model input parameters for the 10 risk groups
and 10 representative patients as well as detailed instructions on
how to run the model, are available from: https://github.com/
miqdadasaria/caliber-scad-model.
RESULTS
The average baseline patient covariates by risk group are shown
in table 1. For the cohort, the mean age at cohort entry was
67 years for males and 72 years for females. Stable angina
(47%) was the most frequent stable-CAD subgroup and STEMI
(7%) the least. One in 10 patients had received PCI within the
previous 6 months, over a quarter had heart failure, nearly one
in ﬁve had depression at the time of stable-CAD diagnosis and
one in six had atrial ﬁbrillation.
There was large variation in CVD risk between the lowest and
highest risk groups, with an absolute difference in 5-year risk
between the lowest and highest risk group of 40.7%. The risk of
clinical events positively correlated with age, higher levels of
CVD risk factors (such as hypertension and diabetes) and higher
prevalence of CVD comorbidities. There were no obvious trends
in the key modiﬁable CVD risk factors such as the lipid proﬁle.
The modelled progression of CVD over time by risk group is
shown in ﬁgure 2. Higher risk groups were predicted to have
much higher levels of CVD mortality compared with lower risk
groups, whereas the latter were predicted to remain event free
for a much longer period and were more likely to die of
non-CVD-related causes.
Summary model results by risk group are shown in table 2.
The risk of all non-fatal events increased with overall CVD risk,
and the risk of non-CVD mortality declined with overall CVD
risk. Lower risk patients were estimated to have greater remain-
ing life expectancy, QALYs and healthcare costs. For low risk
patients (5-year CVD risk 3.5%), the remaining expected dis-
counted lifetime healthcare costs were £62 210, and patients
had 12.0 expected discounted QALYs remaining. For the
highest risk group (5-year CVD risk 44.2%), the remaining
expected discounted lifetime healthcare costs were £35 549,
and patients had 2.8 remaining expected discounted QALYs.
Figure 3 shows the maximum price that the health system
should be willing to pay for new treatments targeted at each risk
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group that reduce CVD hazards by between 10% and 40%.
This maximum price increased with both increasing baseline
risk and with larger treatment effects in terms of proportionate
risk reduction.
More detailed breakdowns of these results as well as results
presented for the representative patients drawn from each risk
group can be found in online supplementary appendix (f).
DISCUSSION
We report the ﬁrst comprehensive lifetime model of stable-CAD
based on long-term EHR data. The model encompasses a full
range of CVD endpoints and accounts for the interdependence
of CVD risks among patients with stable-CAD. The sample
sizes, duration of follow-up and the large number of endpoints
and risk factors captured by the multisource EHR dataset
(CALIBER) provided the opportunity to build a model which
more fully and accurately captured the biological and medical
nuances of such a condition. In quantifying the expected costs,
life expectancy and quality-adjusted life expectancy of patients
with stable-CAD, this analysis provides a means to plan budgets
and services for such patients in the NHS in particular, and in
health systems in developed countries more generally.
We found that at NICE’s lower bound cost-effectiveness
threshold (£20 000 per QALY), a treatment aimed at the lowest
risk patients (5-year risk of 3.5%), would be cost-effective with
annual prices up to £36, £72, £108 or £143 if the treatment
was able to reduce CVD risk by 10%, 20%, 30% and 40%,
respectively. For the highest risk patients (5-year risk of 44.2%),
the respective maximum prices would be £325, £645, £961 or
£1269. For comparison, statins commonly used by these
patients reduce CVD risk by approximately a third28 and cost
£16 per patient per year,29 whereas the annual cost of new anti-
platelet agents can be up to £712 per patient per year.29 These
estimates provide a basis for developers of new medications and
health technologies for stable-CAD to deﬁne necessary effect
sizes that they will need to demonstrate to be considered value
for money by health systems.
In this study it has been shown that using EHR data, in combin-
ation with an analytical model such as that used by NICE in the
English NHS, provides a powerful framework within which to
assess the cost-effectiveness of new technologies. In the many
healthcare systems with constrained budgets, cost-effectiveness
analysis provides a means of comparing the additional health bene-
ﬁts from a new intervention with the health other patients forgo
because expenditure on other types of treatments is necessarily
curtailed in order to ﬁnance the new intervention (opportunity
costs).30 The current analysis uses this approach as a basis for iden-
tifying the minimum treatment effect a new intervention for
stable-CAD will have to achieve at a given price (or the maximum
price for a given treatment effect) and cost-effectiveness threshold.
These necessary treatment effects and prices will inevitably vary
according to patients’ underlying risk of CVD events.
There are very few comparable studies that focus on model-
ling the costs and health effects over the lifetime of patients
with stable-CAD. Studies that we are aware of in this area13 are
typically based on short-term trial data, model only a subset of
Figure 3 Maximum annual price for therapies as a function of baseline 5-year CVD event risk. Each plot within the panel shows the results at a
given cost-effectiveness threshold ranging from £10 000 to £40 000 per QALY. The lines within the plots represent the different efﬁcacies of our
modelled treatments having hazard reductions on CVD endpoints associated with them ranging from 10% to 40%. CVD, cardiovascular disease; MI,
myocardial infarction; QALYs, quality-adjusted life years.
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the relevant CVD endpoints and make predictions over short
time horizons. Models suitable for the economic evaluation of
health technologies in disease areas such as CVD where there
are substantial mortality impacts need to estimate all relevant
healthcare costs and health outcomes over the remaining life-
times of patients. This is why in our study, despite having
10 years of follow-up data, we still required a model to extrapo-
late up to a maximum of 60 years beyond our data to estimate
total lifetime costs and consequences for the full cohort of mod-
elled patients. Limitations of our study are that HRQoL data
were not recorded in the CALIBER dataset and so had to be
drawn from external studies; that changes in prognostic risk
factors over time were not explicitly modelled; instead the equa-
tions underpinning our model were informed by the baseline
values of these risk factors; the dataset we used did not contain
left ventricular ejection fraction which is an important prognos-
tic factor in this patient population; and that the long follow-up
period of our dataset may mean that the modelled risk equa-
tions may not fully reﬂect contemporary risk levels in the popu-
lation. Additionally a number of structural assumptions had to
be made for modelling purposes and these are detailed in online
supplementary appendix (b).
The model we have produced allows policy makers to quan-
tify and understand both the health and the cost burden of
stable-CAD and serves as a basis for evaluating the cost-
effectiveness of new treatments targeted at reducing CVD risk
in this population. Our results suggest that, for the vast majority
of patients with stable-CAD, it is likely that low cost interven-
tions to improve adherence to existing secondary prevention
drugs should be prioritised over high cost new treatments. It is
also notable from our results that, even among the groups with
the highest CVD risk, more patients are predicted to die of
non-CVD-related causes than of CVD-related causes. This high-
lights the vital role of primary care in the holistic management
of both CVD and non-CVD risk for these patients.
Key messages
What is already known on this subject?
▸ Electronic health records have been shown to be useful in
prognosis, but thus far their use in decision analytic models
and cost-effectiveness analysis has been limited.
▸ The recent improvement in acute coronary syndrome
survivorship means that a growing number of people are
living with cardiovascular disease.
What might this study add?
▸ This study provides the ﬁrst lifetime model of the costs and
health effects of patients with stable coronary artery disease
based on long-term linked electronic health records,
predicting key cardiovascular endpoints for these patients
and capturing the interdependence of these endpoints.
How might this impact on clinical practice?
▸ This model can be used to evaluate and to target
appropriately new treatments as they emerge for this patient
population as well as to inform commissioning, pricing and
reimbursement decisions.
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